Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RHOA | P61586 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761495 | 0.91 | CYP3A4 (0.38) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9811267 | 0.89 | TSHR (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9865407 | 0.89 | TSHR (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL2843185 | 0.86 | — | — | |
| SCHEMBL9865572 | 0.84 | CYP3A4 (0.37) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL13861279 | 0.83 | TSHR (0.42) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9413861 | 0.82 | — | — | |
| SCHEMBL9543820 | 0.82 | — | — | |
| SCHEMBL63337 | 0.81 | CYP3A4 (0.35) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1288180 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240429448-A1 | Silicon-Based Energy Storage Devices With Carboxylic Ether, Carboxylic Acid Based Salt, or Acrylate Electrolyte Containing Electrolyte Additives | ENEVATE CORP (US) | 2024-12-26 | — | — | US | claimed |
| US-20210218059-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-07-15 | — | — | US | claimed |
| US-20190190070-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | claimed |
| WO-2019113528-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | claimed |
| US-20240429448-A1 | Silicon-Based Energy Storage Devices With Carboxylic Ether, Carboxylic Acid Based Salt, or Acrylate Electrolyte Containing Electrolyte Additives | ENEVATE CORP (US) | 2024-12-26 | — | — | US | disclosed |
| US-12015122-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2024-06-18 | — | — | US | disclosed |
| US-20210218059-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-20210218059-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| US-10978739-B2 | Silicon-based energy storage devices with carboxylic ether, carboxylic acid based salt, or acrylate electrolyte containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190190070-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2019-06-20 | — | — | US | disclosed |
| WO-2019113528-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH CARBOXYLIC ETHER, CARBOXYLIC ACID BASED SALT, OR ACRYLATE ELECTROLYTE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20160311810-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2016-10-27 | — | — | US | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202795-A1 | 4-Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-26 | — | — | EP | disclosed |
| EP-0202047-A1 | Pyrazolidinium ylides | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4558069-A | TREATMENT OF SKIN DISORDERS | GROUPEMENT D'INTERET ECONOMIQUE DIT: CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1985-12-10 | — | — | US | disclosed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | disclosed |
| US-4464301-A | FOR TREATMENT OF PSORIASIS | GROUPEMENT D'INTERET ECONOMIQUE CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1984-08-07 | — | — | US | disclosed |
| US-4207318-A | ANTIALLERGIC ACTIVITY, BRONCHODILATOR | ROUSSEL UCLAF (FR) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311810-A1 | SYNTHESIS OF RALTEGRAVIR | CYP3A4, CYP3A5, IMPDH1 | CYP3A4 1/4885TSHR 4781/4885MAPT 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.